Novartis pelacarsen trial miss may be cushioned by investor skepticism
Citi says Novartis’ experimental pelacarsen missed the target in a late-stage clinical trial, but the share-price hit could be mitigated by investor skepticism about the study.
An experimental Novartis medicine missed the target in a late-stage clinical trial, but Citi analysts said the share-price impact on the Swiss drugmaker may be limited by investor skepticism about the study. The drug, pelacarsen, reduced the levels of a fatty particle in the trial, but the source text cuts off before providing additional details.